Skip to main content

Advertisement

Table 2 Antimicrobial activity of antimicrobial agents against members of the Enterobacteriaceae collected globally between 2004 - 2013

From: Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004–2013

  MIC 90 (mg/L) MIC range mg/L % susceptible % resistant
Enterobacter spp. (n = 32,987)     
AMK 4 ≤0.5– ≥ 128 97.2 1.8
FEP 8 ≤0.5– ≥ 64 91.7 5.8
CRO 64 ≤0.06– ≥ 128 61.7 35.1
IPM (n = 6,963) 1 ≤0.06– ≥ 32 95.7 1.1
LVX 8 ≤0.008– ≥ 16 86.8 10.7
MEM (n = 26,024) 0.25 ≤0.06– ≥ 32 97.2 1.9
MIN 16 ≤0.5– ≥ 32 73.7 12.5
TZP 128 ≤0.06– ≥ 256 76.1 12.1
TGC 2 ≤0.008– ≥ 32 95.4 1.1
Enterobacter spp., Car-R (n = 578)    
AMK ≥128 ≤0.5– ≥ 128 68.3 23.7
FEP ≥64 ≤0.5– ≥ 64 35.6 52.2
CRO ≥128 ≤0.06– ≥ 128 6.7 91.9
LVX ≥16 ≤0.008– ≥ 16 39.1 54.0
MIN ≥32 ≤0.5– ≥ 32 39.8 38.8
TZP ≥256 ≤0.06– ≥ 256 22.5 60.7
TGC 4 0.06–16 83.0 5.2
Escherichia coli (n = 37,038)   
AMK 8 ≤0.5– ≥ 128 98.3 0.9
AMC 32 ≤0.12– ≥ 64 66.6 14.2
AMP ≥64 ≤0.5– ≥ 64 35.6 63.5
FEP 16 ≤0.5– ≥ 64 88.5 9.0
CRO 64 ≤0.06– ≥ 128 79.1 19.9
IPM (n = 8,091) 0.5 ≤0.06– ≥ 32 99.4 0.3
LVX ≥16 ≤0.008– ≥ 16 66.1 31.5
MEM (n = 28,947) ≤0.06 ≤0.06– ≥ 32 99.1 0.5
MIN 16 ≤0.5– ≥ 32 77.0 13.0
TZP 16 ≤0.06– ≥ 256 91.3 4.4
TGC 0.5 ≤0.008– ≥ 32 >99.9 <0.1
Escherichia coli, ESBL-positive (n = 5,178)   
AMK 16 ≤0.5– ≥ 128 94.2 2.7
AMC 32 0.25– ≥ 64 31.3 28.5
AMP ≥64 1– ≥ 64 0.4 99.5
FEP ≥64 ≤0.5– ≥ 64 32.4 54.8
CRO ≥128 ≤0.06– ≥ 128 1.3 97.5
IPM (n = 643) 0.5 ≤0.06–8 98.1 0.6
LVX ≥16 ≤0.008– ≥ 16 18.1 78.5
MEM (n = 4,535) 0.12 ≤0.06– ≥ 32 98.5 0.8
MIN ≥32 ≤0.5– ≥ 32 63.2 22.7
TZP 64 ≤0.06– ≥ 256 77.0 9.9
TGC 0.5 ≤0.008–8 >99.9 <0.1
Escherichia coli, Car-R (n = 181)    
AMK ≥128 ≤0.5– ≥ 128 50.8 38.1
AMC ≥64 2– ≥ 64 11.6 76.8
AMP ≥64 1– ≥ 64 8.3 90.6
FEP ≥64 ≤0.5– ≥ 64 28.2 56.4
CRO ≥128 ≤0.06– ≥ 128 9.9 90.1
LVX ≥16 ≤0.008– ≥ 16 22.7 71.3
MIN ≥32 ≤0.5– ≥ 32 43.1 35.4
TZP ≥256 1– ≥ 256 29.3 55.8
TGC 2 ≤0.008–16 97.2 1.7
Klebsiella oxytoca (n = 6,940)   
AMK 4 ≤0.5– ≥ 128 98.8 0.8
AMC 32 0.25– ≥ 64 79.4 12.4
FEP 2 ≤0.5– ≥ 64 96.1 2.4
CRO 16 ≤0.06– ≥ 128 81.5 16.2
IPM (n = 1,454) 0.5 ≤0.06– ≥ 32 99.2 0.5
LVX 2 ≤0.008– ≥ 16 92.1 5.7
MEM (n = 5,486) 0.12 ≤0.06– ≥ 32 98.8 0.8
MIN 8 ≤0.5– ≥ 32 88.2 5.6
TZP ≥256 ≤0.06– ≥ 256 85.1 12.5
TGC 1 ≤0.008–16 98.7 0.2
Klebsiella pneumoniae (n = 28,928)   
AMK 16 ≤0.5– ≥ 128 94.4 3.1
AMC 32 ≤0.12– ≥ 64 67.9 20.2
FEP ≥64 ≤0.5– ≥ 64 81.0 15.8
CRO ≥128 ≤0.06– ≥ 128 70.1 28.8
IPM (n = 6,008) 0.5 ≤0.06– ≥ 32 97.7 1.6
LVX ≥16 ≤0.008– ≥ 16 77.4 19.5
MEM (n = 22,920) 0.25 ≤0.06– ≥ 32 93.5 5.4
MIN 16 ≤0.5– ≥ 32 71.4 18.0
TZP ≥256 ≤0.06– ≥ 256 79.4 14.9
TGC 2 ≤0.008– ≥ 32 95.3 0.8
Klebsiella pneumoniae, ESBL-positive (n = 5,899)   
AMK 32 ≤0.5– ≥ 128 83.6 9.5
AMC ≥64 ≤0.12– ≥ 64 18.3 48.3
FEP ≥64 ≤0.5– ≥ 64 31.9 56.6
CRO ≥128 ≤0.06– ≥ 128 1.4 97.0
IPM (n = 946) 1 ≤0.06– ≥ 32 91.3 6.1
LVX ≥16 ≤0.008– ≥ 16 35.2 57.1
MEM (n = 4,953) 2 ≤0.06– ≥ 32 88.3 9.0
MIN ≥32 ≤0.5– ≥ 32 48.4 34.5
TZP ≥256 ≤0.06– ≥ 256 44.3 39.2
TGC 2 ≤0.008– ≥ 32 92.3 1.6
Klebsiella pneumoniae, Car-R (n = 1,330)    
AMK ≥128 ≤0.5– ≥ 128 57.5 18.4
AMC ≥64 1– ≥ 64 1.7 96.5
FEP ≥64 ≤0.5– ≥ 64 7.4 85.0
CRO ≥128 ≤0.06– ≥ 128 1.8 97.5
LVX ≥16 ≤0.008– ≥ 16 10.1 85.9
MIN ≥32 ≤0.5– ≥ 32 52.2 25.3
TZP ≥256 0.12– ≥ 256 4.7 91.3
TGC 2 0.03–16 92.0 2.1
Klebsiella pneumoniae, ESBL-positive, Car-R (n = 505)   
AMK ≥128 ≤0.5– ≥ 128 59.8 15.6
AMC ≥64 8– ≥ 64 0.8 96.2
FEP ≥64 1– ≥ 64 4.8 83.6
CRO ≥128 2– ≥ 128 0.0 99.6
LVX ≥16 0.015– ≥ 16 6.7 88.5
MIN ≥32 ≤0.5– ≥ 32 49.7 28.5
TZP ≥256 1– ≥ 256 2.0 92.9
TGC 2 0.12–16 91.1 3.6
Serratia marcescens (n = 13,006)   
AMK 8 ≤0.5– ≥ 128 96.5 2.1
AMC ≥64 ≤0.12– ≥ 64 3.3 93.9
AMP (n = 12,963) ≥64 ≤0.5– ≥ 64 2.7 88.0
FEP 2 ≤0.5– ≥ 64 95.2 3.5
CRO 16 ≤0.06– ≥ 128 79.6 16.9
IPM (n = 2,865) 1 ≤0.06–8 92.2 1.2
LVX 2 ≤0.008– ≥ 16 92.9 4.4
MEM (n = 10,141) 0.25 ≤0.06– ≥ 32 97.4 1.9
MIN 8 ≤0.5– ≥ 32 72.3 8.5
TZP 16 ≤0.06– ≥ 256 92.4 3.2
TGC 2 ≤0.008– ≥ 32 95.8 0.7
Serratia marcescens, Car-R (n = 229)    
AMK ≥128 ≤0.5– ≥ 128 67.7 24.9
AMC ≥64 ≤0.12– ≥ 64 0.4 99.1
AMP ≥64 16– ≥ 64 0.0 95.2
FEP ≥64 ≤0.5– ≥ 64 51.1 39.3
CRO ≥128 ≤0.06– ≥ 128 26.2 70.3
LVX ≥16 0.03– ≥ 16 60.7 31.0
MIN 16 ≤0.5– ≥ 32 54.6 26.6
TZP ≥256 0.25– ≥ 256 45.4 41.0
TGC 4 0.12–16 83.8 4.8
  1. AMK, amikacin; AMC, amoxicillin-clavulanate; AMP, ampicillin; BL, β-lactamase; Car-R, carbapenem-resistant; FEP, cefepime; CAZ, ceftazidime; CRO, ceftriaxone; ESBL, extended-spectrum β-lactamase; IPM, imipenem; LVX, levofloxacin; LZD, linezolid; MEM, meropenem; MIN, minocycline; PEN, penicillin; TZP, piperacillin-tazobactam; TGC, tigecycline; VAN, vancomycin.